| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/26/2008 | US20080153740 Methods for increasing protein polyethylene glycol (PEG) conjugation |
| 06/26/2008 | US20080153131 Free of transmembrane domain; immunoglobulins; autoimmune diseases |
| 06/26/2008 | US20080153107 Isolated PGE synthase, provided from encoding nucleic acid. Methods of production and use. Assays for modulators, especially inhibitors, of PGE synthase activity. |
| 06/26/2008 | US20080152738 Oil-in-water emulsions; agglutination; evaporation; lectin |
| 06/26/2008 | US20080152737 Plant extracts; cosmetics; galactolipids |
| 06/26/2008 | US20080152702 Improved blood circulation lifetime of drug-carrying liposomes having a surface coating of releasable hydrophilic polymer covalently and reversibly linked to an phospholipid or polypeptide through a dithiobenzyl linkage |
| 06/26/2008 | US20080152666 Apoptosis-inducing polypeptides |
| 06/26/2008 | US20080152665 Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response |
| 06/26/2008 | US20080152663 Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer |
| 06/26/2008 | US20080152655 Using immunoglobulin specific to cytotoxic t-lymphocyte antigen-4 receptor as therapeutic in treatment of cell proliferative disorders; immunotherapy; tissue targeted therapy |
| 06/26/2008 | US20080152652 Stem cell factor specific immunoglobulin for use in prevention and treatment of blood disorders |
| 06/26/2008 | US20080152651 Beta-like glycoprotein hormone polypeptide specific immunoglobulin for treatment of autoimmune, inflammatory, (such as rheumatoid arthritis, psoriasis, multiple sclerosis, toxic shock, bone marrow and organ transplantation disorders |
| 06/26/2008 | US20080152650 Methods and Compositions For Specifically Targeting Human Hepatocellular Carcinoma Cells |
| 06/26/2008 | US20080152647 Using MG1(mucin) specific immunoglobulins to target therapeutic agents to tumor cells |
| 06/26/2008 | US20080152646 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 06/26/2008 | US20080152642 Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| 06/26/2008 | US20080152633 Flavivirus Replicon Constructs for Tumor Therapy |
| 06/26/2008 | US20080152631 Cancer Antigen Peptides Derived from Wt1 |
| 06/26/2008 | US20080152618 Using tumor necrosis factor superfamily of ligands as therapeutic tool in treatment and prevention of cell proliferative disorders |
| 06/26/2008 | US20080152616 Amphiphilic block copolymer and polymeric compostition comprising the same for drug delivery |
| 06/26/2008 | US20080152594 Targeting vector-phospholipid conjugates |
| 06/26/2008 | US20080152588 Metal Chelators and Methods of Their Use |
| 06/26/2008 | US20080152587 TARGETED BINDING AGENTS DIRECTED TO uPAR AND USES THEREOF |
| 06/26/2008 | DE102006062264A1 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen Use of xanthohumol for preventing and / or combating liver disease |
| 06/26/2008 | DE102006062203A1 Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen Substituted 5H-pyrimido [5,4-b] indoles as inducers of apoptosis in B-CLL cells |
| 06/26/2008 | DE102006061913A1 New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula |
| 06/26/2008 | DE102006060598A1 New tetrahydrobenzoisoxazole compounds are mitotic motor protein Eg5 modulators useful to treat and prevent cancer, and to treat e.g. monocyte leukemia, glioblastoma, colon carcinoma, myelotic leukemia and lymphatic leukemia |
| 06/26/2008 | DE102006060344A1 Pharmazeutische Zusammensetzung, Verwendung der pharmazeutischen Zusammensetzung zur Behandlung eines Hirntumors, Herstellungsverfahren derselben sowie ein Kit of parts enthaltend die pharmazeutische Zusammensetzung Pharmaceutical composition, use of the pharmaceutical composition for the treatment of a brain tumor, manufacturing method thereof, and a kit of parts comprising the pharmaceutical composition |
| 06/26/2008 | CA2673717A1 Method for administration of pegylated liposomal doxorubicin |
| 06/26/2008 | CA2673591A1 Chemical compounds |
| 06/26/2008 | CA2673582A1 Pyridine benzamides and pyrazine benzamides used as pkd inhibitors |
| 06/26/2008 | CA2673564A1 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| 06/26/2008 | CA2673451A1 Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 06/26/2008 | CA2673417A1 Radioprotective benzimidazole compounds and related methods |
| 06/26/2008 | CA2673095A1 Indazole derivatives as kinase inhibitors for the treatment of cancer |
| 06/26/2008 | CA2673040A1 Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| 06/26/2008 | CA2672983A1 Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature |
| 06/26/2008 | CA2672937A1 Inhibitory polynucleotide compositions and methods for treating cancer |
| 06/26/2008 | CA2672841A1 Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety |
| 06/26/2008 | CA2672828A1 Methods of treatment |
| 06/26/2008 | CA2672815A1 Benzimidazole derivatives for use in treating abnormal cell growth |
| 06/26/2008 | CA2672784A1 Anti-tumour immunity induction by a non-replicatmg adenovirus encoding tap-1 |
| 06/26/2008 | CA2672673A1 O-linked pyrimidin-4-amine-based compounds, compositions comprising them and methods of their use |
| 06/26/2008 | CA2672668A1 4-amino-1h-pyrimidin-2-one-based compounds, compositions comprising them and methods of their use |
| 06/26/2008 | CA2672622A1 Human antibodies to human delta like ligand 4 |
| 06/26/2008 | CA2672618A1 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| 06/26/2008 | CA2672521A1 Pyrazole derivatives as protein kinase inhibitors |
| 06/26/2008 | CA2672270A1 Treatments of therapy resistant diseases and drug combinations for treating the same |
| 06/26/2008 | CA2672192A1 Inhibitors of histone deacetylase and prodrugs thereof |
| 06/26/2008 | CA2671982A1 Methods of using mek inhibitors |
| 06/26/2008 | CA2671738A1 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| 06/26/2008 | CA2671734A1 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| 06/26/2008 | CA2670992A1 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| 06/26/2008 | CA2669921A1 Human monoclonal antibodies to btla and methods of use |
| 06/25/2008 | EP1935978A1 Method of controlling decomposition of protein by tetracycline antibiotic |
| 06/25/2008 | EP1935899A1 Nucleotide and protein sequence of mammastatin and methods of use |
| 06/25/2008 | EP1935874A1 S1p3 receptor antagonist |
| 06/25/2008 | EP1935869A1 Retinoids for the treatment of emphysema |
| 06/25/2008 | EP1935436A1 Nanoparticle clusters and methods for forming same |
| 06/25/2008 | EP1935431A2 Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
| 06/25/2008 | EP1935427A2 Methods for treating rheumatoid diseases using a soluble CTLA4 mutant molecule |
| 06/25/2008 | EP1935423A2 Composition for treating and/or prophylaxis of tumors of the breast |
| 06/25/2008 | EP1935415A2 Treatment of androgen-deprivation induced osteoporosis |
| 06/25/2008 | EP1935413A1 Iontophoresis preparation for treatment of breast cancer and/or mastitis |
| 06/25/2008 | EP1934262A1 Antibodies to complementary peptides of thrombin or portions thereof |
| 06/25/2008 | EP1934259A2 Nanobodies and polypeptides against egfr and igf-ir |
| 06/25/2008 | EP1934257A2 Proteasome inhibiting beta lactam compounds |
| 06/25/2008 | EP1934256A2 Hepatocyte growth factor receptor splice variants and methods of using same |
| 06/25/2008 | EP1934248A2 Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications |
| 06/25/2008 | EP1934241A2 Novel series of imidazolyl substituted steroidal and indan-1-one derivatives |
| 06/25/2008 | EP1934228A2 Raf inhibitor compounds and methods of use thereof |
| 06/25/2008 | EP1934225A1 Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors |
| 06/25/2008 | EP1934224A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer |
| 06/25/2008 | EP1934213A1 Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| 06/25/2008 | EP1934200A1 Tyrosine kinase inhibitors |
| 06/25/2008 | EP1934185A1 Pyrazole compounds that modulate hsp90 activity |
| 06/25/2008 | EP1933945A1 A pharmaceutical composition comprising mahanine useful for the treatment of prostate cancer |
| 06/25/2008 | EP1933879A2 Bioconjugates comprising sulfated polysaccharides and their uses |
| 06/25/2008 | EP1933872A2 Anti-glypican-3 antibody |
| 06/25/2008 | EP1933871A2 Human monoclonal antibodies to activin receptor-like kinase-1 |
| 06/25/2008 | EP1933857A2 Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| 06/25/2008 | EP1933847A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| 06/25/2008 | EP1933844A1 Combination |
| 06/25/2008 | EP1933842A2 5-lipoxygenase-activating protein (flap) inhibitors |
| 06/25/2008 | EP1933832A2 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| 06/25/2008 | EP1933831A2 Modulators of atp-binding cassette transporters |
| 06/25/2008 | EP1933824A2 Hydrazone agents to treat cutaneous lesions |
| 06/25/2008 | EP1933820A2 Palmarumycin based inhibitors of thioredoxin and methods of using same |
| 06/25/2008 | EP1846441B1 Riproximin , a novel type ii ribosome-inactivating protein and uses thereof |
| 06/25/2008 | EP1811994B1 Novel derivatives of porphyrin, particularly chlorins and bacteriochlorins, and uses thereof in photodynamic therapy |
| 06/25/2008 | EP1616950B1 Peptide having htlv-1-specific ctl-inducing activity |
| 06/25/2008 | EP1556375B1 Flavone derivatives as inhibitors of cyclin-dependent kinases |
| 06/25/2008 | EP1492534B1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 06/25/2008 | EP1485345B1 Urokinase inhibitors, production and use thereof |
| 06/25/2008 | EP1418931B1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain |
| 06/25/2008 | EP1377164B1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 06/25/2008 | EP1322321B1 Use of S-[2,3-Bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK (MALP-2) |
| 06/25/2008 | EP1286962B1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 06/25/2008 | EP1278535B1 Uses of tgap7 for the modulation of leucocyte activation |
| 06/25/2008 | EP1190055B1 Human endogenous retrovirus |